Transcell Oncologics’s cell based platforms portfolio Transtoxbio inks a commercial agreement with Vipragen Biosciences, a Contract Research Organization offering preclinical services to global Pharma
Published Date: December 2019
Transcell Oncologics’s cell-based platforms portfolio Transtoxbio inks a commercial agreement with Vipragen Biosciences, a Contract Research Organization offering preclinical services to global Pharma
For Precision All the Way – Exploratory to Regulatory
The process of developing a drug or any cosmetics for human application is time consuming and costly. Discovery and development in this context involves screening, identification of hits, converting hits to leads, optimization of leads, testing safety in the exploratory stage till regulatory profiling to qualify for clinical trials. To increase the chances of successfully completing a clinical trial that can lead to the approval entering markets, the choice of appropriate preclinical models is of paramountprominence
Developing a safe andthe drug of choice requires thorough preclinical testings,that could evaluate aspects of pharmacodynamics, pharmacokinetics toxicology invitro and in vivoscenery. Pharma has been for ever racing to enter clinics after employing traditionally known preclinical models. It is NOW or NEVER a situation for the industry to embrace preclinical systems that mimic human physiology with powers to predict the fate in clinics.
If one has to know about the powers, ace prediction capabilities in preclinical stage, models built on human sourced adult stem cells find it’s spot with no debate while the assay performed will capture the read outs ranging from simple to complex opening the scope for big data mining and analysis.
With cosmetics industry and with the ban on animal testings, it is compelling a situation and the need to adopt alternative platforms in preclinical settings starting from exploratory stage. Preclinical systems built on human sourced stem cells are ideal models to be integrated for evaluating induced toxicogenomics, carcinogenicity testing, epidermal sensitivity, penetration tests, and mutagenicity.
Vipragen Biosciences, Mysuru, India that provides contract research services in areas of Biology, Toxicology, Pharmacology, DMPK, Drug Discovery and other Pre-clinical research areas has entered into an agreement to partner with Transcell Oncologics’ cell-based products portfolio (www.transtoxbio.com). Through this cooperation, Vipragen sources cell-based platforms from Transcell to offer specialty predictive discovery preclinical services like: Chemical libraries screening, Phenotype based testings, Invitro toxicity screening, PDX based evaluations, Receptor binding assays, Tumorigenicity, Mutagenicity, Small molecules in stem cell renewal and differentiation.
This collaboration will facilitate the development and validation ofrange of new in vitroassays.
About www.transtoxbio.com portfolio:
All human biological discards sourced primary progenitor adult stem cells based platforms that can predict toxicity related endpoints. Additionally, some of these platforms have capabilities to humanize either animals or biomaterials, transdifferentiate to organ-specific cells like human hepatocytes, cardiocytes, beta cells, bone, cartilage with documented applications/use cases in preclinics addressing pharmaceuticals, cosmeceutical industry need.